A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects

OBJECTIVE: SB2, a biosimilar to infliximab reference product (INF), has an identical amino acid sequence and similar physicochemical functional properties to its reference product. The primary objective of this study is to demonstrate pharmacokinetic (PK) bioequivalence between SB2 and EU-sourced IN...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BioDrugs
Autores principales: Shin, Donghoon, Kim, Youngdoe, Kim, Yoo Seok, Körnicke, Thomas, Fuhr, Rainard
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4684585/
https://ncbi.nlm.nih.gov/pubmed/26577771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-015-0150-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares